Lilly to Invest $3 Billion in China to Boost Obesity Pill (1)

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity market.

Much of the investment will be devoted to setting up manufacturing of orforglipron, the weight-loss pill currently under regulatory review in China, Lilly said in a WeChat statement Wednesday. To complement its own capacity, Lilly plans to partner with local companies such as Pharmaron Beijing Pharmaceutical Co., which has a $200 million deal to build the technical capabilities to produce the ...